Our Pipeline

Addressing Neurodegenerative Disorders

As a clinical-stage therapeutic device company, we are committed to developing a next-generation treatment for neurodegenerative disorders through the eyes. Our research to date has yielded a light administration protocol and a combination of intensities and wavelengths and has led to our proprietary specialized phototherapy technology—with an initial focus on treating Parkinson’s disease.

Early data suggests that specialized phototherapy can provide clinical benefit in other neurodegenerative and neuropsychiatric disorders. We are working to validate this data and begin clinical work to address these large unmet needs and provide safe and effective treatments to those who need it most.